Amedeo Smart

Free Medical Literature Service



Bladder Cancer

  Free Subscription

Articles published in
    May 2018
  1. SMITH AB, Chisolm S, Deal A, Spangler A, et al
    Patient-centered prioritization of bladder cancer research.
    Cancer. 2018 May 4. doi: 10.1002/cncr.31530.
    >> Share

    April 2018
  2. JAZZAR U, Yong S, Klaassen Z, Huo J, et al
    Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States.
    Cancer. 2018 Apr 16. doi: 10.1002/cncr.31404.
    >> Share

  3. CORREA AF, Smaldone MC
    Melancholia and cancer: The bladder cancer narrative.
    Cancer. 2018 Apr 16. doi: 10.1002/cncr.31402.
    >> Share

    January 2018
  4. CHOUDHURY A, Hoskin PJ
    Bladder cancer and the National Cancer Data Base: New insight or misinformation?
    Cancer. 2018 Jan 16. doi: 10.1002/cncr.31210.
    >> Share

    December 2017
  5. WELTY CJ, Sanford TH, Wright JL, Carroll PR, et al
    The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy.
    Cancer. 2017;123:4574-4582.
    >> Share

    July 2017
  6. CAHN DB, Handorf EA, Ghiraldi EM, Ristau BT, et al
    Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
    Cancer. 2017 Jul 25. doi: 10.1002/cncr.30900.
    >> Share

  7. VETTERLEIN MW, Wankowicz SAM, Seisen T, Lander R, et al
    Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
    Cancer. 2017 Jul 25. doi: 10.1002/cncr.30907.
    >> Share

  8. KOPP RP, Stratton KL, Glogowski E, Schrader KA, et al
    Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
    Cancer. 2017;123:2452-2458.
    >> Share

  9. PIATON E, Advenier AS, Carre C, Decaussin-Petrucci M, et al
    p16/Ki-67 dual labeling and urinary cytology results according to the New Paris System for Reporting Urinary Cytology: Impact of extended follow-up.
    Cancer. 2017;125:552-562.
    >> Share

    June 2017
  10. OJERHOLM E, Smith A, Hwang WT, Christodouleas JP, et al
    Reply to Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710.
    Cancer. 2017 Jun 30. doi: 10.1002/cncr.30871.
    >> Share

  11. DOLAN RD, McMillan DC
    Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710.
    Cancer. 2017 Jun 30. doi: 10.1002/cncr.30872.
    >> Share

  12. KORPICS MC, Block AM, Martin B, Hentz C, et al
    Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy.
    Cancer. 2017 Jun 5. doi: 10.1002/cncr.30719.
    >> Share

  13. RIMAR KJ, Tran PT, Matulewicz RS, Hussain M, et al
    The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
    Cancer. 2017;123:1912-1924.
    >> Share

  14. SCOTT SN, Ostrovnaya I, Lin CM, Bouvier N, et al
    Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guerin.
    Cancer. 2017;125:416-426.
    >> Share

    February 2017
  15. PACKIAM VT, Johnson SC, Steinberg GD
    Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Guerin.
    Cancer. 2017;123:390-400.
    >> Share

  16. WANG H, Hoda RS, Faquin W, Rossi ED, et al
    FNA biopsy of secondary nonlymphomatous malignancies in salivary glands: A multi-institutional study of 184 cases.
    Cancer. 2017;125:91-103.
    >> Share

  17. MACLEOD LC, Pham KN, Agoff SN, Dahl KL, et al
    Cytologic persistence of malignant cells after transurethral resection of bladder tumors: Implications for concomitant manipulation of the urinary tract at the time of endoscopic resection.
    Cancer. 2017;125:114-119.
    >> Share

    October 2016
  18. OJERHOLM E, Smith A, Hwang WT, Baumann BC, et al
    Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710.
    Cancer. 2016 Oct 27. doi: 10.1002/cncr.30422.
    >> Share

    August 2016
  19. PRINTZ C
    Arsenic in private well water may contribute to bladder cancer risk.
    Cancer. 2016;122:2291.
    >> Share

  20. DESAI NB, Scott SN, Zabor EC, Cha EK, et al
    Genomic characterization of response to chemoradiation in urothelial bladder cancer.
    Cancer. 2016 Aug 1. doi: 10.1002/cncr.30219.
    >> Share

    May 2016
  21. ROSE TL, Deal AM, Nielsen ME, Smith AB, et al
    Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer.
    Cancer. 2016 May 25. doi: 10.1002/cncr.30029.
    >> Share

    Mind the gap: What is driving the survival disparity between the sexes in bladder cancer?
    Cancer. 2016 May 25. doi: 10.1002/cncr.30027.
    >> Share

    March 2016
  23. ROSS JS, Wang K, Khaira D, Ali SM, et al
    Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
    Cancer. 2016;122:702-11.
    >> Share

  24. TULLY CM, Apolo AB, Zabor EC, Regazzi AM, et al
    The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents.
    Cancer. 2016;122:712-21.
    >> Share

    January 2016
  25. CHOU R, Selph SS, Buckley DI, Gustafson KS, et al
    Treatment of muscle-invasive bladder cancer: A systematic review.
    Cancer. 2016 Jan 15. doi: 10.1002/cncr.29843.
    >> Share

    December 2015
  26. GREEN AK, Milowsky MI
    Genomic profiling of advanced bladder cancer to guide the use of targeted therapeutics.
    Cancer. 2015 Dec 9. doi: 10.1002/cncr.29825.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016